Nanomedicine and experimental tuberculosis: Facts, flaws, and future

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 3, 2011, Pages 259-272

  Pandey, Rajesh ^a,b   Ahmad, Zahoor ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b MAHARISHI MARKANDESHWAR INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

Author keywords

Chemotherapy; Drug delivery; Nanomedicine; Polymers; Tuberculosis

Indexed keywords

ADVERSE EFFECT; CHOICE OF CARRIER; CHRONIC DISEASE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; EXPERIMENTAL DATA; LARGE-SCALE PRODUCTION; NANOMEDICINES; SUSTAINED RELEASE; TUBERCULOSIS;

CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; MEDICAL NANOTECHNOLOGY; NATURAL POLYMERS; POLYMERS;

DRUG INTERACTIONS;

4 METHOXYCINNAMIC ACID 2 ETHYLHEXYL ESTER; ALGINIC ACID; AZATHIOPRINE; CLOFAZIMINE; CLOTRIMAZOLE; CYCLOSPORIN; DANAZOL; DIGITOXIN; ECONAZOLE; ENBUCRILATE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ITRACONAZOLE; METRONIDAZOLE; MOXIFLOXACIN; NANOPARTICLE; POLY(3 HYDROXYBUTYRIC ACID); POLY(ORTHO ESTER); POLYACRYLAMIDE; POLYANHYDRIDE; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; PROPRANOLOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMULSION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; REFLUX ESOPHAGITIS; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79956366828     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.01.009     Document Type: Review

References (124)

1. Pandey R., Khuller G.K. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv 2004, 1:195-201.
2. Sun Z., Zhang J., Song H., Zhang X., Li Y., Tian M., et al. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2010, 14:1436-1441.
3. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010, 10:621-629.
4. Bulut-Oner F., Capan Y., Kas S., Oner L., Hincal A.A. Sustained release isoniazid tablets. I. Formulation and in vitro evaluation. Farmaco 1989, 44:739-752.
5. Muhuri G., Pal T.K. Computation of release kinetics of isoniazid microcapsules. Boll Chim Farm 1991, 130:169-171.
6. Jain R., Shah N.H., Malick A.W., Rhodes C.T. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm 1998, 24:703-727.
7. Gangadharam P.R., Ashtekar D.R., Farhi D.C., Wise D.L. Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer. Tubercle 1991, 72:115-122.
8. Kailasam S., Wise D.L., Gangadharam P.R. Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infection in beige mice following a single implant of a biodegradable polymer. J Antimicrob Chemother 1994, 33:273-279.
9. Gangadharam P.R., Kailasam S., Srinivasan S., Wise D.L. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. J Antimicrob Chemother 1994, 33:265-271.
10. Kailasam S., Daneluzzi D., Gangadharam P.R. Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer. Tuber Lung Dis 1994, 75:361-365.
11. Gangadharam P.R., Geeta N., Hsu Y.Y., Wise D.L. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. Int J Tuberc Lung Dis 1999, 3:515-520.
12. Dutt M., Khuller G.K. Poly (d,l-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin. Indian J Exp Biol 2000, 38:887-894.
13. Dutt M., Khuller G.K. Sustained release of isoniazid from a single injectable dose of poly (d,l-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents 2001, 17:115-122.
14. Khopade A.J., Jain N.K. A stable multiple emulsion system bearing isoniazid: preparation and characterization. Drug Dev Ind Pharm 1998, 24:289-293.
15. Dutt M., Khuller G.K. Chemotherapy of Mycobacterium tuberculosis infections in mice by combination of isoniazid and rifampicin drugs entrapped in poly (d,l-lactide-co-glycolide) microparticles. J Antimicrob Chemother 2001, 47:829-835.
16. Dutt M., Khuller G.K. Therapeutic efficacy of poly (d,l-lactide-co-glycolide) encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 2001, 45:363-366.
17. Barrow E.L.W., Winchester G.A., Staas J.K., Quenelle D.C., Barrow W.W. Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 1998, 42:2682-2689.
18. Quenelle D.C., Staas J.K., Winchester G.A., Barrow E.L., Barrow W.W. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 1999, 43:1144-1151.
19. Ain Q., Sharma S., Garg S.K., Khuller G.K. Role of poly (d,l-lactide-co-glycolide) in development of sustained oral delivery system for antitubercular drug(s). Int J Pharm 2002, 239:34-46.
20. Ain Q., Sharma S., Khuller G.K. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampicin and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother 2003, 47:3005-3007.
21. Hauck T.S., Giri S., Gao Y., Chan W.C. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv Drug Deliv Rev 2010, 62:438-448.
22. Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Lecompte T., et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002, 105:230-235.
23. Horisawa E., Hirota Kawazoe T.S., Yamada J., Yamamoto H., Takeuchi H., Kawashima Y. Prolonged anti-inflammatory action of d,l-lactide/glycolide copolymer nanospheres containing betamethazone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 2002, 19:403-410.
24. Jacobs C., Müller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002, 19:189-194.
25. Ahlin P., Kristl J., Kristl A., Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 2002, 239:113-120.
26. Lamprecht A., Ubrich N., Hombreiro Pérez M., Lehr C., Hoffman M., Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 1999, 184:97-105.
27. Lamprecht A., Ubrich N., Yamamoto H., Schäfer U., Takeuchi H., Maincent P., et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001, 299:775-781.
28. Mainardes R.M., Evangelista R.C. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005, 290:137-144.
29. Jaiswal J., Gupta S.K., Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release 2004, 96:169-178.
30. Bilati U., Pasquarello C., Corthals G.L., Hochstrasser D.F., Allémann E., Doelker E. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for quantitation and molecular stability assessment of insulin entrapped within PLGA nanoparticles. J Pharm Sci 2005, 94:688-694.
31. Alvarez-Román R., Naik A., Kalia Y.N., Guy R.H., Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004, 21:1818-1825.
32. Guzmán M., Aberturas M.R., Rodríguez-Puyol M., Molpeceres J. Effect of nanoparticles on digitoxin uptake and pharmacologic activity in rat glomerular mesangial cell cultures. Drug Deliv 2000, 7:215-222.
33. Prakobvaitayakit M., Nimmannit U. Optimization of polylactic-co-glycolic acid nanoparticles containing itraconazole using 2(3) factorial design. AAPS PharmSciTech 2003, 4:E71.
34. Pandey R., Ahmad Z., Sharma S., Khuller G.K. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm 2005, 301:268-276.
35. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents 2008, 31:142-146.
36. Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387-422.
37. Pandey R., Ahmed Z., Sharma S., Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003, 83:373-378.
38. Sharma A., Pandey R., Sharma S., Khuller G.K. Chemotherapeutic efficacy of poly (d,l-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004, 24:599-604.
39. Bastian I., Rigouts L., Van Deun A., Portaels F. Directly observed treatment, short course strategy and multidrug-resistant tuberculosis: are any modifications required?. Bulletin WHO 2000, 78:238-251.
40. Pandey R., Sharma S., Khuller G.K. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006, 13:287-294.
41. Johnson C.M., Pandey R., Sharma S., Khuller G.K., Basaraba R.J., Orme I.M., et al. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:4335-4338.
42. Oganesian E.A., Bud'ko A.P., Stukalov I.u.V., Liubimov I.I., Biketov S.F., Sveshnikov P.G., et al. Development and estimation of nanosomal rifampicin. Antibiot Khimioter 2005, 50:15-19.
43. Moretton M.A., Glisoni R.J., Chiappetta D.A., Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces 2010, 79:467-479.
44. Lis H., Sharon N. Lectins as molecules and as tools. Annu Rev Biochem 1986, 55:35-67.
45. Lehr C.M. Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release 2000, 65:19-29.
46. Clark M.A., Hirst B.H., Jepson M.A. Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev 2000, 43:207-223.
47. Abu-Dahab R., Schäfer U.F., Lehr C.M. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci 2001, 14:37-46.
48. Sharma A., Sharma S., Khuller G.K. Lectin functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004, 54:761-766.
49. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005, 55:430-435.
50. Gaspar M.M., Cruz A., Fraga A.G., Castro A.G., Cruz M.E., Pedrosa J. Developments on drug delivery systems for the treatment of mycobacterial infections. Curr Top Med Chem 2008, 8:579-591.
51. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., Prasad B. Poly (d,l-lactide-co-glycolide) nanoparticle based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003, 52:981-986.
52. Sung J.C., Padilla D.J., Garcia-Contreras L., Verberkmoes J.L., Durbin D., Peloquin C.A., et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009, 26:1847-1855.
53. Ohashi K., Kabasawa T., Ozeki T., Okada H. One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 2009, 135:19-24.
54. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosol for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004, 269:37-49.
55. Sung J.C., Garcia-Contreras L., Verberkmoes J.L., Peloquin C.A., Elbert K.J., Hickey A.J., et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother 2009, 53:1338-1343.
56. Garcia-Contreras L., Sung J.C., Muttil P., Padilla D., Telko M., Verberkmoes J.L., et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010, 54:1436-1442.
57. Morello M., Krone C.L., Dickerson S., Howerth E., Germishuizen W.A., Wong Y.L., et al. Dry powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis (Edinb) 2009, 89:371-377.
58. Fiegel J., Garcia-Contreras L., Thomas M., Verberkmoes J., Elbert K., Hickey A., et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 2008, 25:805-811.
59. Pulliam B., Sung J.C., Edwards D.A. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv 2007, 4:651-663.
60. Pandey R., Khuller G.K. Subcutaneous nanoparticle based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 2004, 54:266-268.
61. Saraogi G.K., Sharma B., Joshi B., Gupta P., Gupta U.D., Jain N.K., et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target 2010, [Epub ahead of print]. PMID: 20540651.
62. Ravi Kumar M.N. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000, 3:234-258.
63. Tønnesen H.H., Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm 2002, 28:621-630.
64. Hejazi R., Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003, 89:151-165.
65. Joseph I., Venkataram S. Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates. Int J Pharm 1995, 126:161-168.
66. González-Rodríguez M.L., Holgado M.A., Sánchez-Lafuente C., Rabasco A.M., Fini A. Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002, 232:225-234.
67. Takka S., Acartürk F. Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsulation 1999, 16:275-290.
68. Chickering D.E., Jacob J.S., Desai T.A., Harrison M., Harris W.P., Morrel C.N., et al. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug loaded alginate and poly (fumaric-co-sebacic anhydride) microspheres. J Control Release 1997, 48:35-46.
69. Lannuccelli V., Coppi G., Cameroni R. Biodegradable intraoperative system for bone infection treatment. I. The drug/polymer interaction. Int J Pharm 1996, 143:195-201.
70. Cui J.H., Goh J.S., Park S.Y., Kim P.H., Lee B.J. Preparation and physical characterization of alginate microparticles using air atomization method. Drug Dev Ind Pharm 2001, 27:309-319.
71. Whitehead L., Collett J.H., Fell J.T. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000, 210:45-49.
72. Woitiski C.B., Neufeld R.J., Veiga F., Carvalho R.A., Figueiredo I.V. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci 2010, 41:556-563.
73. Nanjwade B.K., Singh J., Parikh K.A., Manvi F.V. Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles. Int J Pharm 2010, 385:176-180.
74. Lucinda-Silva R.M., Evangelista R.C. Microspheres of alginate-chitosan containing isoniazid. J Microencapsulation 2003, 20:145-152.
75. Ain Q., Sharma S., Khuller G.K., Garg S.K. Alginate based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003, 51:931-938.
76. Pandey R., Khuller G.K. Chemotherapeutic potential of alginate chitosan microspheres as antitubercular drugs. J Antimicrob Chemother 2004, 53:635-640.
77. Takka S., Ocak O.H., Acartürk F. Formulation and investigation of nicardipine HCl-alginate gel beads with factorial design-based studies. Eur J Pharm Sci 1998, 6:241-246.
78. Rajaonarivony M., Vauthier C., Couarraze G., Puisieux F., Couvreur P. Development of a new drug carrier made from alginate. J Pharm Sci 1993, 82:912-917.
79. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006, 27:409-416.
80. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci 2006, 48:171-176.
81. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Evaluation of antitubercular drug loaded alginate nanoparticles against experimental tuberculosis. Nanoscience 2005, 1:81-85.
82. Ahmad Z., Sharma S., Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005, 26:298-303.
83. Ahmad Z., Khuller G.K. Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv 2008, 5:1323-1334.
84. Saraogi G.K., Gupta P., Gupta U.D., Jain N.K., Agrawal G.P. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010, 385:143-149.
85. Jenning V., Lippacher A., Gohla S.H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsulation 2002, 19:1-10.
86. Muller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004, 113:151-170.
87. Kim B.D., Na K., Choi H.K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 2005, 24:199-205.
88. Prego C., García M., Torres D., Alonso M.J. Transmucosal macromolecular drug delivery. J Control Release 2005, 101:151-162.
89. Zara G.P., Bargoni A., Cavalli R., Fundarò A., Vighetto D., Gasco M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002, 91:1324-1333.
90. Yu B.T., Sun X., Zhang Z.R. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res 2003, 26:1096-1101.
91. Pandey R., Khuller G.K. Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005, 85:227-234.
92. Pandey R., Sharma S., Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 2005, 85:415-420.
93. Katti M.K. Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis. Med Sci Monit 2004, 10:RA215-29.
94. Tosi G., Rivasi F., Gandolfi F., Costantino L., Vandelli M.A., Forni F. Conjugated poly (d,l-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 2005, 26:4189-4195.
95. Das D., Lin S. Double-coated poly (butylcyanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci 2005, 94:1343-1353.
96. Joshi S.A., Chavhan S.S., Sawant K.K. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010, 76:189-199.
97. Kabanov A.V., Batrakova E.V. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004, 10:1355-1363.
98. Lockman P.R., Koziara J.M., Mumper R.J., Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004, 12:635-641.
99. Pandey R., Khuller G.K. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother 2006, 57:1146-1152.
100. Sosnik A., Carcaboso A.M., Glisoni R.J., Moretton M.A., Chiappetta D.A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010, 62:547-559.
101. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
102. Lalloo U.G., Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep 2010, 7:143-151.
103. Lopes E., Pohlman A.R., Bassani V., Guterres S.S. Polymeric colloidal systems containing ethionamide: preparation and physicochemical characterization. Pharmazie 2000, 55:527-530.
104. Kumar G., Sharma S., Shafiq N., Pandhi P., Khuller G.K., Malhotra S. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv 2011, 18:65-73.
105. Ahmad Z., Sharma S., Khuller G.K. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007, 3:239-243.
106. Kisich K.O., Gelperina S., Higgins M.P., Wilson S., Shipulo E., Oganesyan E., et al. Encapsulation of moxifloxacin within poly (butylcyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int J Pharm 2007, 345:154-162.
107. Ahmad Z., Sharma S. Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against M. tuberculosis H37Rv. FEMS Microbiol Lett 2005, 251:19-22.
108. Ahmad Z., Sharma S., Khuller G.K. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006, 261:181-186.
109. Ahmad Z., Sharma S., Khuller G.K., Singh P., Faujdar J., Katoch V.M. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2006, 28:543-544.
110. Ahmad Z., Sharma S., Khuller G.K. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 2006, 258:200-203.
111. Nuermberger E.L., Yoshimatsu T., Tyagi S., Williams K., Rosenthal I., O'Brien R.J., et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004, 170:1131-1134.
112. Pandey R., Khuller G.K. Nanoparticle-based oral drug delivery system for an injectable antibiotic- streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007, 53:437-441.
113. World Health Organization (WHO) [home page on the Internet]. Treatment of tuberculosis: guidelines for national programmes 2003, WHO, Geneva, WHO/CDS/TB/2003.313. Available from: http://www.who.int/tb/publications/2003/en/index1.html. 3rd ed.
114. Wang C., Hickey A.J. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech 2010, 11:538-549.
115. Kumar A., Patel G., Menon S.K. Fullerene isoniazid conjugate-a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity. Chem Biol Drug Des 2009, 73:553-557.
116. http://www.drugs.com/pro/zoladex.html.
117. Pandey R., Sharma S., Khuller G.K. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications. Indian J Exp Biol 2006, 44:459-467.
118. Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr Respir Rev 2007, 8:62-66.
119. Semete B., Booysen L., Lemmer Y., Kalombo L., Katata L., Verschoor J., et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed Nanotechnol Biol Med 2010, 6:662-671.
120. Boisselier E., Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38:1759-1782.
121. Kurmi B.D., Kayat J., Gajbhiye V., Tekade R.K., Jain N.K. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010, 7:781-794.
122. Weers J.G., Bell J., Chan H.K., Cipolla D., Dunbar C., Hickey A.J., et al. Pulmonary formulations: what remains to be done?. J Aerosol Med Pulm Drug Deliv 2010, 23(Suppl 2):S5-S23.
123. Nuermberger E.L., Spigelman M.K., Yew Y.Y. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010, 15:764-778.
124. Barry C.E., Duncan K. Tuberculosis-strategies towards antiinfectives for a chronic disease. Drug Discov Today 2004, 1:491-496.